AIPD expands nootropic ingredient portfolio with introduction of the Cognilipid brands

AIDP Inc. is introducing the Cognilipid portfolio of brands to its portfolio of nootropic ingredients. This includes CogniPLUS, CogniPS, and CogniPA.

AIDP Inc. (City of Industry, CA) is introducing the Cognilipid portfolio of brands to its portfolio of nootropic ingredients. This includes CogniPLUS, CogniPS, and CogniPA. CogniPLUS is a proprietary branded complex of phospholipids including phosphatidylserine and phosphatidic acid with manufacturing and use patents that is supported by human clinical studies to support stress, memory, mood, and premenstrual syndrome (PMS) symptoms. Two clinical studies provide evidence that CogniPLUS supports cognitive health, with subjects recording higher memory, learning, association, and information gathering scores after three months. A PMS study found that the ingredient decreased symptoms by 19% over four menstrual cycles.

CogniPS is a branded phosphatidylserine and CogniPA is a branded phosphatidic acid, both of which have a patent on exclusive solvent free manufacturing processes. Both ingredients are synergistic lipid complexes formulated to support cognitive health and performance. AIDP is partnering with Lipogen Israel for this family of products. The company has been innovating and manufacturing phospholipids since 1991, and was the first to introduce phosphatidylserine (PS) globally and clinically test soy-lecithin-based PS.

“AIDP is excited to introduce the Cognilipid brand of products into our cognitive health solutions portfolio” said Mark Thurston, president of AIDP, in a press release. “Consumers and our customers are looking for new clinically supported nootropic solutions as the market continues to expand.”